Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

DSHEA 1994: The Regulatory Root Cause

Why US Supplements Are Not Premarket-Tested

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Statute defining FDA's (limited) supplement authority

Reference only. Not medical advice.

What can go wrong

The framework's core risk is informational asymmetry: consumers reasonably assume regulatory vetting that does not exist. Downstream consequences include adulterated products reaching market, dose and label inaccuracy, and delayed diagnosis when men self-treat. Enforcement is reactive and under-resourced relative to the size of the market.

This is something to take to a clinician. The Atlas can tell you what is known about dshea 1994: the regulatory root cause in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

The Dietary Supplement Health and Education Act of 1994 (DSHEA, Pub. L. 103-417) is the single legal fact that explains the entire supplement-quality problem. Under DSHEA, dietary supplements, unlike drugs, require no FDA pre-market approval for safety or efficacy. Ingredients sold before October 15, 1994 are grandfathered; only a genuinely 'new dietary ingredient' triggers a safety notification. The FDA is largely relegated to post-market enforcement, acting only after a product is already on shelves and shown to be unsafe, misbranded, or adulterated. This is the structural reason 'testosterone boosters' can be sold despite little evidence they work.

The law that made 'sold widely' and 'proven' two different things.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Defines the legal category of dietary supplements
  • Sets the (low) bar for marketing claims and structure/function statements
  • Explains why T-boosters, nootropics, and 'natural enhancement' products proliferate

Structure/function claims: the loophole in plain sight

DSHEA lets makers use 'structure/function' claims, 'supports healthy testosterone levels,' 'promotes vitality', without proving them, provided they add the disclaimer that the statement is not FDA-evaluated and the product is not intended to diagnose, treat, cure, or prevent disease. This carefully bounded language is how a product with no efficacy data can legally imply a testosterone benefit. The consumer hears 'supports testosterone'; the law hears 'we promised nothing specific.'

What people get wrong

  • Often saidIf it is sold legally, the FDA checked that it works

    ActuallyFalse. DSHEA requires no pre-market efficacy or safety approval. The FDA generally acts only after a marketed product is shown to be harmful or adulterated.

  • Often said'Supports healthy testosterone' is a proven claim

    ActuallyIt is a structure/function claim that requires no proof and carries a mandatory disclaimer. It is marketing language, not a substantiated medical claim.

Who profits, and who pushes back

  • Pieter Cohen

    Pushes backInternist, Harvard Medical School; supplement-safety researcher

    Under DSHEA, the FDA cannot require products to be proven safe or effective before sale, and it lacks the resources to police a market this large after the fact.

How we got here

DSHEA passed Congress in 1994 after an intense industry-backed lobbying and consumer campaign that framed proposed FDA oversight as a threat to vitamin access. The result was a compromise that placed the burden of proof on the FDA to demonstrate a product is unsafe, rather than on the manufacturer to demonstrate it is safe and effective before sale, the inverse of the drug-approval paradigm. The 2007 cGMP (current Good Manufacturing Practice) rules added manufacturing-quality requirements, and the 2006 adverse-event reporting law (AER) required serious-event reporting, but neither restored pre-market efficacy review.

  1. 1994DSHEA enacted; supplements exempted from pre-market approval
  2. 2006Dietary Supplement and Nonprescription Drug Consumer Protection Act mandates serious adverse-event reporting
  3. 2007FDA finalizes cGMP rules for supplement manufacturing
  4. 2010s-2020sRepeated FDA tainted-product alerts and JAMA analyses expose adulteration the framework struggles to prevent

Set against the alternatives

The contrast with the drug pathway is total: a prescription testosterone product must clear FDA efficacy and safety review before sale and faces ongoing monitoring; a 'testosterone booster' faces neither. Third-party certifications (NSF, USP, Informed Sport) exist precisely because the statutory baseline is so low.

What we do not know

  • Would mandatory product registration and pre-market safety review meaningfully reduce adulteration?
  • Should structure/function claims require any substantiation?
  • Can the FDA's post-market model ever scale to a market of tens of thousands of products?

At a glance

Statute
Pub. L. 103-417 (DSHEA 1994)
Pre-market approval
Not required for supplements
Grandfather date
October 15, 1994
FDA's main lever
Post-market enforcement (after harm)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about DSHEA 1994: The Regulatory Root Cause. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.